BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38754594)

  • 1. Testing the disintegration and texture-related palatability predictions for orodispersible tablets using an instrumental tool coupled with multivariate analysis: Focus on process variables and analysis settings.
    Iovanov R; Cornilă A; Bogdan C; Hales D; Tomuță I; Achim M; Tăut A; Iman N; Casian T; Iurian S
    Eur J Pharm Sci; 2024 Jul; 198():106801. PubMed ID: 38754594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of oral formulation-dependent characteristics of orodispersible tablets using texture profiles and multivariate data analysis.
    Casian T; Bogdan C; Tarta D; Moldovan M; Tomuta I; Iurian S
    J Pharm Biomed Anal; 2018 Apr; 152():47-56. PubMed ID: 29414018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor.
    Uchida T; Yoshida M; Hazekawa M; Haraguchi T; Furuno H; Teraoka M; Ikezaki H
    J Pharm Pharmacol; 2013 Sep; 65(9):1312-20. PubMed ID: 23927469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
    Krupa A; Jachowicz R; Pędzich Z; Wodnicka K
    AAPS PharmSciTech; 2012 Dec; 13(4):1120-9. PubMed ID: 22941425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.
    Petrovick GF; Kleinebudde P; Breitkreutz J
    Eur J Pharm Biopharm; 2018 Jan; 122():137-145. PubMed ID: 29106946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
    Kokott M; Lura A; Breitkreutz J; Wiedey R
    Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New advances in the characterization of lyophilised orally disintegrating tablets.
    Vanbillemont B; Everaert H; De Beer T
    Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
    Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets.
    Mahesparan VA; Bin Abd Razak FS; Ming LC; Uddin AH; Sarker MZI; Bin LK
    Int J Pharm Compd; 2020; 24(2):148-155. PubMed ID: 32196477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability.
    Takano H; Uchida S; Kashiwagura Y; Tanaka S; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(2):112-119. PubMed ID: 30713270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of oral disintegration time of fast disintegrating tablets using texture analyzer and computational optimization.
    Szakonyi G; Zelkó R
    Int J Pharm; 2013 May; 448(2):346-53. PubMed ID: 23558313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
    Hobbs D; Karagianis J; Treuer T; Raskin J
    Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression.
    Kande KV; Kotak DJ; Degani MS; Kirsanov D; Legin A; Devarajan PV
    AAPS PharmSciTech; 2017 Aug; 18(6):2055-2066. PubMed ID: 27995465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.